Literature DB >> 10618372

Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease.

B Gooptu1, B Hazes, W S Chang, T R Dafforn, R W Carrell, R J Read, D A Lomas.   

Abstract

The serpins are a family of proteinase inhibitors that play a central role in the control of proteolytic cascades. Their inhibitory mechanism depends on the intramolecular insertion of the reactive loop into beta-sheet A after cleavage by the target proteinase. Point mutations within the protein can allow aberrant conformational transitions characterized by beta-strand exchange between the reactive loop of one molecule and beta-sheet A of another. These loop-sheet polymers result in diseases as varied as cirrhosis, emphysema, angio-oedema, and thrombosis, and we recently have shown that they underlie an early-onset dementia. We report here the biochemical characteristics and crystal structure of a naturally occurring variant (Leu-55-Pro) of the plasma serpin alpha(1)-antichymotrypsin trapped as an inactive intermediate. The structure demonstrates a serpin configuration with partial insertion of the reactive loop into beta-sheet A. The lower part of the sheet is filled by the last turn of F-helix and the loop that links it to s3A. This conformation matches that of proposed intermediates on the pathway to complex and polymer formation in the serpins. In particular, this intermediate, along with the latent and polymerized conformations, explains the loss of activity of plasma alpha(1)-antichymotrypsin associated with chronic obstructive pulmonary disease in patients with the Leu-55-Pro mutation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618372      PMCID: PMC26617          DOI: 10.1073/pnas.97.1.67

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema.

Authors:  R Mahadeva; D A Lomas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

2.  Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins.

Authors:  M Wilczynska; M Fa; J Karolin; P I Ohlsson; L B Johansson; T Ny
Journal:  Nat Struct Biol       Date:  1997-05

Review 3.  Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation.

Authors:  P R Elliott; J P Abrahams; D A Lomas
Journal:  J Mol Biol       Date:  1998-01-23       Impact factor: 5.469

Review 4.  Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.

Authors:  R Huber; R W Carrell
Journal:  Biochemistry       Date:  1989-11-14       Impact factor: 3.162

5.  Cloning, expression, purification, and biological activity of recombinant native and variant human alpha 1-antichymotrypsins.

Authors:  H Rubin; Z M Wang; E B Nickbarg; S McLarney; N Naidoo; O L Schoenberger; J L Johnson; B S Cooperman
Journal:  J Biol Chem       Date:  1990-01-15       Impact factor: 5.157

6.  A kinetic mechanism for the polymerization of alpha1-antitrypsin.

Authors:  T R Dafforn; R Mahadeva; P R Elliott; P Sivasothy; D A Lomas
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

7.  Stimulatory effect of inflammatory cytokines on alpha 1-antichymotrypsin expression in human lung-derived epithelial cells.

Authors:  J Cichy; J Potempa; R K Chawla; J Travis
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

8.  alpha 1-Antichymotrypsin in lung secretions is not an effective proteinase inhibitor.

Authors:  G Berman; S C Afford; D Burnett; R A Stockley
Journal:  J Biol Chem       Date:  1986-10-25       Impact factor: 5.157

9.  The molecular basis of alpha 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease.

Authors:  J P Faber; W Poller; K Olek; U Baumann; J Carlson; B Lindmark; S Eriksson
Journal:  J Hepatol       Date:  1993-07       Impact factor: 25.083

10.  alpha 1-Antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo. Evidence for the C sheet mechanism of polymerization.

Authors:  D A Lomas; P R Elliott; S K Sidhar; R C Foreman; J T Finch; D W Cox; J C Whisstock; R W Carrell
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

View more
  51 in total

1.  Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.

Authors:  P R Elliott; X Y Pei; T R Dafforn; D A Lomas
Journal:  Protein Sci       Date:  2000-07       Impact factor: 6.725

Review 2.  Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy.

Authors:  David A Lomas; Ravi Mahadeva
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Probing serpin conformational change using mass spectrometry and related methods.

Authors:  Yuko Tsutsui; Anindya Sarkar; Patrick L Wintrode
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

Review 4.  How do proteins avoid becoming too stable? Biophysical studies into metastable proteins.

Authors:  Lisa D Cabrita; Stephen P Bottomley
Journal:  Eur Biophys J       Date:  2003-09-19       Impact factor: 1.733

5.  Defining the mechanism of polymerization in the serpinopathies.

Authors:  Ugo I Ekeowa; Joanna Freeke; Elena Miranda; Bibek Gooptu; Matthew F Bush; Juan Pérez; Jeff Teckman; Carol V Robinson; David A Lomas
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

Review 6.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

7.  Structural mechanism for the carriage and release of thyroxine in the blood.

Authors:  Aiwu Zhou; Zhenquan Wei; Randy J Read; Robin W Carrell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

8.  The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.

Authors:  Yu-Ran Na; Hana Im
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

9.  Kinetic intermediates en route to the final serpin-protease complex: studies of complexes of α1-protease inhibitor with trypsin.

Authors:  Ashoka A Maddur; Richard Swanson; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

10.  Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome.

Authors:  Sabina Janciauskiene; Torsten Krakau
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.